Grover 1990.

Methods	Randomisation method not stated Double‐blind placebo‐controlled trial with parallel groups 80 women randomised No loss to follow‐up given but details of numbers randomised sketchy No power calculation made
Participants	India 80 women aged 19–50 years with a subjective complaint of menorrhagia and normal cervical cytology and secretory endometrium (after D&C) Exclusion criteria: local pelvic causes of bleeding
Interventions	Group 1: MFA 500 mg 3 times daily for 5 days of menstruation or until menstruation ceased, n = 40 Group 2: placebo same dosage regimen, n = 40 Duration: 3 consecutive cycles
Outcomes	"Relief" of menorrhagia Number of days bleeding
Notes	Not stated if ITT analysis No details given regarding measurement of "relief" of menorrhagia No data given for number of days bleeding in placebo group Author could not be contacted for clarification
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Unclear risk	Unclear risk
Blinding (performance bias and detection bias) All outcomes	Low risk	Double blind
Incomplete outcome data (attrition bias) All outcomes	Low risk	No dropouts reported
Other bias	Unclear risk	No details given regarding measurement of "relief" of menorrhagia No data given for number of days bleeding in placebo group Author could not be contacted for clarification